BIND-014 is a targeted polymeric nanoparticle,[1] and is an investigational therapeutic drug in phase 2 clinical trials for various cancers,[2] eg. metastatic prostate cancer[3]
BIND-014 is an Accurin nanomedicine produced by Bind Therapeutics Inc.[1] BIND-014 targets prostate-specific membrane antigen (PSMA), which is expressed on prostate cancer cells and the blood vessels of many types of solid tumors, and contains docetaxel[1] as the cytotoxic agent.
Positive results in non-small cell lung cancer were presented in late 2014.[1]

^ a b c d BIND Therapeutics Presents Positive Phase 2 Results Highlighting Potential of BIND-014 as Novel Anti-Cancer Treatment at Q3W Dosing Schedule for Patients with Non-small Cell Lung Cancer at 26th EORTC-NCI-AACR Annual Symposium
^ A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck (iNSITE2)
^ A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer

This medical treatment–related article is a stub. You can help Wikipedia by expanding it.